Article info

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Authors

  1. Correspondence to Dr Kevin L Winthrop, Oregon Health & Science University, Portland, OR 97239, USA; winthrop{at}ohsu.edu
View Full Text

Citation

Winthrop KL, Tanaka Y, Takeuchi T, et al
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Publication history

  • Received June 22, 2021
  • Accepted September 18, 2021
  • First published November 5, 2021.
Online issue publication 
January 12, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.